Bruno Baillavoine - CEL SCI Independent Director
| CVM Stock | USD 0.60 0.10 14.29% |
Director
Mr. Bruno Baillavoine is an Independent Director of the Company. Mr. Baillavoine was the Director, Head of Pericles Group UK the subsidiary of the Paris based leading French consulting firm, Pericles Consulting Holdings SAS. Pericles is an expert in the field of Banking, Finance, Asset Management and Insurance with over 350 institutional clients. He has also been an advisor to the Board of CSL Inc, Combatives Sports League a US Mix Martial Arts company since 2017 and was appointed to the Board in 2019. Between 20102016, Mr. Baillavoine was a partner of Globomass Holdings Limited, a London, England based developer of renewable energy projects from concept through final operations. From 20122016 Mr. Baillavoine was the Executive Chairman of Globomass Holdings. Globomass was acquired by CleanBay Inc. in 2016. Mr. Baillavoine remains a significant sharehold in CleanBay Inc. Between 1978 and 1982 he was the marketing manager of Ravenhead Ltd., a manufacturer of glass tableware, and part of United Distillers Group . During this time Mr. Baillavoine became the UK Business Manager where he restored market share and profit for United Distillers. From 1982 to 1986 Mr. Baillavoine was Group Corporationrationrate Planning and Group Marketing Director for Prontaprint where he expanded the number of shops to 500 locations in four years since 2015.
| Age | 65 |
| Tenure | 9 years |
| Address | 8229 Boone Boulevard, Vienna, VA, United States, 22182 |
| Phone | 703 506 9460 |
| Web | https://cel-sci.com |
CEL SCI Management Efficiency
The company has Return on Asset of (0.6141) % which means that on every $100 spent on assets, it lost $0.6141. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (2.502) %, meaning that it generated no profit with money invested by stockholders. CEL SCI's management efficiency ratios could be used to measure how well CEL SCI manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of December 2024, Return On Tangible Assets is likely to drop to -1.01. In addition to that, Return On Capital Employed is likely to drop to -1.52. At this time, CEL SCI's Total Assets are very stable compared to the past year. As of the 28th of December 2024, Non Current Assets Total is likely to grow to about 28.5 M, while Return On Tangible Assets are likely to drop (1.01).Similar Executives
| Found 3 records | DIRECTOR Age | ||
| Paul McBarron | Cyclacel Pharmaceuticals | 63 | |
| Brian MD | Cyclacel Pharmaceuticals | 62 | |
| Gill Christie | Cyclacel Pharmaceuticals | 67 | |
Management Performance
| Return On Equity | -2.5 | ||||
| Return On Asset | -0.61 |
CEL SCI Corp Leadership Team
Elected by the shareholders, the CEL SCI's board of directors comprises two types of representatives: CEL SCI inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CEL. The board's role is to monitor CEL SCI's management team and ensure that shareholders' interests are well served. CEL SCI's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CEL SCI's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Young, Independent Director | ||
| Giovanni MD, Acting Officer | ||
| Geert Kersten, Chief Executive Officer, Treasurer, Director | ||
| Robert Watson, Independent Director | ||
| John Cipriano, Senior Vice President - Regulatory Affairs | ||
| Patricia Prichep, Senior Vice President - Operations, Corporate Secretary | ||
| Bruno Baillavoine, Independent Director | ||
| Geert Esq, Treasurer Officer | ||
| Eyal Talor, Chief Scientific Officer | ||
| Daniel Zimmerman, Senior Vice President - Research, Cellular Immunology |
CEL Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CEL SCI a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.5 | ||||
| Return On Asset | -0.61 | ||||
| Current Valuation | 50.04 M | ||||
| Shares Outstanding | 63.81 M | ||||
| Shares Owned By Insiders | 2.91 % | ||||
| Shares Owned By Institutions | 10.46 % | ||||
| Number Of Shares Shorted | 4.43 M | ||||
| Price To Earning | (1.14) X | ||||
| Price To Book | 4.52 X | ||||
| Price To Sales | 11,797 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in CEL SCI Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CEL SCI. If investors know CEL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CEL SCI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.63) | Return On Assets (0.61) | Return On Equity (2.50) |
The market value of CEL SCI Corp is measured differently than its book value, which is the value of CEL that is recorded on the company's balance sheet. Investors also form their own opinion of CEL SCI's value that differs from its market value or its book value, called intrinsic value, which is CEL SCI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CEL SCI's market value can be influenced by many factors that don't directly affect CEL SCI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CEL SCI's value and its price as these two are different measures arrived at by different means. Investors typically determine if CEL SCI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CEL SCI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.